GlobeNewsWire
27 May 2026, 12:47 UTC · 17w ago
Verdict
Headline takes no side. We score AIM +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
The WHO has declared the Bundibugyo strain (BDBV) Ebola outbreak a Public Health Emergency of International Concern (PHEIC), for which there is currently no approved specific treatment or vaccine.
So whatCreates an urgent, high-demand market environment for any viable therapeutic countermeasure, increasing the valuation potential for companies with relevant drug candidates.
More positive than 87% of claims this week
AIM ImmunoTech's lead drug, Ampligen, demonstrated 100% survival in a mouse model following lethal doses of Ebola in previously published Biosafety Level 4 pre-clinical studies.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 79% of claims this week
Ampligen has already received Orphan Drug designation for Ebola virus disease from both the FDA and the EMA.
More positive than 66% of claims this week
AIM ImmunoTech will release a Virtual Investor presentation on June 4, 2026, detailing the potential role of Ampligen as a prophylactic or early-onset treatment for Ebola.
More positive than 53% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company is highlighting positive pre-clinical data for its drug Ampligen in the context of a WHO-declared Ebola emergency.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
8h ago
−18.3%
Price is moving against the score
$0.1901 vs $0.2327 close before publication (May 26) · not market-adjusted
AIM chart →
